We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BASF's Aseptrol Business to be Acquired by Oxidium Technologies
Read MoreHide Full Article
Key Takeaways
BASF sells its Aseptrol technology portfolio to Oxidium Technologies to streamline focus on core segments.
BASFY aligns divestment with its "Winning Ways" strategy, targeting growth in core areas.
Oxidium plans to expand Aseptrol's reach using existing networks, with no disruption to supply or services.
BASF SE (BASFY - Free Report) recently entered into an agreement with Oxidium Technologies LLC to sell its Aseptrol technology portfolio, marking a strategic step in sharpening its focus by supporting growth in prioritized market segments. The details of the transaction were not disclosed. Oxidium Technologies will deploy the Aseptrol platform across new industries, sectors and use cases.
The product line was originally acquired by BASFY from Engelhard Corporation in 2006. The Aseptrol chlorine dioxide is used in various applications, including water purification, disinfection, and dental line cleaning. The divestment is aligned with BASFY’s “Winning Ways” strategy, which aims to optimize portfolio and target growth in core areas.
For Oxidium Technologies, the acquisition represents an opportunity to further develop Aseptrol to achieve its full potential. Oxidium will also leverage existing distribution networks, including Aseptrol’s largest, Quip Laboratories, to unlock broader footprint. As all existing formulations, regulatory approvals, and support services remain unchanged, there will be no interruption in supply or support.
BASFY stock has gained 1.5% over the past year against the industry’s 6.1% decline.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Agnico Eagle Mines Limited (AEM - Free Report) , Compañía de Minas Buenaventura S.A.A. (BVN - Free Report) and Balchem Corporation (BCPC - Free Report) .
The Zacks Consensus Estimate for AEM’s 2026 earnings is pegged at $13.28 per share, indicating a rise of 60.39% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 10.77%. AEM’s shares have soared 74.5% over the past year.
The Zacks Consensus Estimate for BVN’s 2026 earnings is pinned at $3.88 per share, indicating a 17.58% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 80.4%. BVN’s shares have jumped 104.7% over the past year.
The Zacks Consensus Estimate for BCPC’s 2026 earnings is pinned at $5.47 per share, indicating a 6.2% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the four trailing quarters, while missing it in the remaining two.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
BASF's Aseptrol Business to be Acquired by Oxidium Technologies
Key Takeaways
BASF SE (BASFY - Free Report) recently entered into an agreement with Oxidium Technologies LLC to sell its Aseptrol technology portfolio, marking a strategic step in sharpening its focus by supporting growth in prioritized market segments. The details of the transaction were not disclosed. Oxidium Technologies will deploy the Aseptrol platform across new industries, sectors and use cases.
The product line was originally acquired by BASFY from Engelhard Corporation in 2006. The Aseptrol chlorine dioxide is used in various applications, including water purification, disinfection, and dental line cleaning. The divestment is aligned with BASFY’s “Winning Ways” strategy, which aims to optimize portfolio and target growth in core areas.
For Oxidium Technologies, the acquisition represents an opportunity to further develop Aseptrol to achieve its full potential. Oxidium will also leverage existing distribution networks, including Aseptrol’s largest, Quip Laboratories, to unlock broader footprint. As all existing formulations, regulatory approvals, and support services remain unchanged, there will be no interruption in supply or support.
BASFY stock has gained 1.5% over the past year against the industry’s 6.1% decline.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Agnico Eagle Mines Limited (AEM - Free Report) , Compañía de Minas Buenaventura S.A.A. (BVN - Free Report) and Balchem Corporation (BCPC - Free Report) .
While AEM and BVN sport a Zacks Rank #1 (Strong Buy) each at present, BCPC carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for AEM’s 2026 earnings is pegged at $13.28 per share, indicating a rise of 60.39% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 10.77%. AEM’s shares have soared 74.5% over the past year.
The Zacks Consensus Estimate for BVN’s 2026 earnings is pinned at $3.88 per share, indicating a 17.58% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 80.4%. BVN’s shares have jumped 104.7% over the past year.
The Zacks Consensus Estimate for BCPC’s 2026 earnings is pinned at $5.47 per share, indicating a 6.2% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in two of the four trailing quarters, while missing it in the remaining two.